Camelid single-domain antibodies: Historical perspective and future outlook

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Arbabi Ghahroudi, Mehdi ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b CARLETON UNIVERSITY   (Canada)

Author keywords

Antibody engineering; Camelid single domain antibody; Heavy chain antibody; Nanobody; Therapeutic antibody; VHH

Indexed keywords

ANTIBODY; CAPLACIZUMAB; GLYCOPROTEIN; HLA DR5 ANTIGEN; INTERLEUKIN 6; NANOBODY; SERUM ALBUMIN; SNAKE VENOM;

ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BIOLOGY; BIOPHYSICS; BLOOD CLOTTING; CAMELID; CONCEPTUAL FRAMEWORK; EVOLUTION; EVOLUTIONARY ADAPTATION; HISTORICAL RESEARCH; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOGENETICS; MEDICAL ONTOLOGY; NONHUMAN; PLATELET AGGREGATION ASSAY; PROTEIN EXPRESSION; PUBLICATION; REPRODUCIBILITY; RHEUMATOID ARTHRITIS; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 85034626127     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01589     Document Type: Article

References (102)

1. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature (1993) 363:446-8. doi:10.1038/363446a0
2. Wernery U. Camelid immunoglobulins and their importance for the new-born-a review. J Vet Med B Infect Dis Vet Public Health (2001) 48:561-8. doi:10.1111/j.1439-0450.2001.00478.x
3. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem (2013) 82:775-97. doi:10.1146/annurev-biochem-063011-092449
4. van der Linden R, de Geus B, Stok W, Bos W, van Wassenaar D, Verrips T, et al. Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J Immunol Methods (2000) 240:185-95. doi:10.1016/S0022-1759(00)00188-5
5. Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods (2006) 3:887-9. doi:10.1038/nmeth953
6. Maass DR, Sepulveda J, Pernthaner A, Shoemaker CB. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods (2007) 324:13-25. doi:10.1016/j.jim.2007.04.008
7. De Simone EA, Saccodossi N, Ferrari A, Leoni J. Development of ELISAs for the measurement of IgM and IgG subclasses in sera from llamas (Lama glama) and assessment of the humoral immune response against different antigens. Vet Immunol Immunopathol (2008) 126:64-73. doi:10.1016/j.vetimm.2008.06.015
8. Blanc MR, Anouassi A, Ahmed Abed M, Tsikis G, Canepa S, Labas V, et al. A one-step exclusion-binding procedure for the purification of functional heavy-chain and mammalian-type gamma-globulins from camelid sera. Biotechnol Appl Biochem (2009) 54:207-12. doi:10.1042/BA20090208
9. Franklin EC, Lowenstein J, Bigelow B, Meltzer M. Heavy chain disease-a new disorder of serum gamma-globulins: report of the first case. Am J Med (1964) 37:332-50. doi:10.1016/0002-9343(64)90191-3
10. Alexander A, Steinmetz M, Barritault D, Frangione B, Franklin EC, Hood L, et al. gamma heavy chain disease in man: cDNA sequence supports partial gene deletion model. Proc Natl Acad Sci U S A (1982) 79:3260-4. doi:10.1073/pnas.79.10.3260
11. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett (1997) 414:521-6. doi:10.1016/S0014-5793(97)01062-4
12. Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrips T, et al. The crystal structure of a llama heavy chain variable domain. Nat Struct Biol (1996) 3:752-7. doi:10.1038/nsb0996-752
13. Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, Hamers R, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol (1996) 3:803-11. doi:10.1038/nsb0996-803
14. Arbabi Ghahroudi M. Generation and Characterization of Phage-Displayed Camel Single-Domain Antibodies [Ph.D. Dissertation]. Brussels (Belgium): Vrije Universiteit Brussel (VUB) (1996)
15. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, De Genst E, et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J (1998) 17:3512-20. doi:10.1093/emboj/17.13.3512
16. Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng (1994) 7:1129-35. doi:10.1093/protein/7.9.1129
17. Vu KB, Ghahroudi MA, Wyns L, Muyldermans S. Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol (1997) 34:1121-31. doi:10.1016/S0161-5890(97)00146-6
18. Achour I, Cavelier P, Tichit M, Bouchier C, Lafaye P, Rougeon F. Tetrameric and homodimeric camelid IgGs originate from the same IgH locus. J Immunol (2008) 181:2001-9. doi:10.4049/jimmunol.181.3.2001
19. Nguyen VK, Hamers R, Wyns L, Muyldermans S. Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire. EMBO J (2000) 19:921-30. doi:10.1093/emboj/19.5.921
20. Nguyen VK, Muyldermans S, Hamers R. The specific variable domain of camel heavy-chain antibodies is encoded in the germline. J Mol Biol (1998) 275:413-8. doi:10.1006/jmbi.1997.1477
21. De Genst E, Saerens D, Muyldermans S, Conrath K. Antibody repertoire development in camelids. Dev Comp Immunol (2006) 30:187-98. doi:10.1016/j.dci.2005.06.010
22. Conrath KE, Wernery U, Muyldermans S, Nguyen VK. Emergence and evolution of functional heavy-chain antibodies in Camelidae. Dev Comp Immunol (2003) 27:87-103. doi:10.1016/S0145-305X(02)00071-X
23. Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LG, de Geus B. Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol (2000) 37:579-90. doi:10.1016/S0161-5890(00)00081-X
24. Klarenbeek A, El Mazouari K, Desmyter A, Blanchetot C, Hultberg A, de Jonge N, et al. Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform. MAbs (2015) 7:693-706. doi:10.1080/19420862.2015.1046648
25. Deschacht N, De Groeve K, Vincke C, Raes G, De Baetselier P, Muyldermans S. A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire. J Immunol (2010) 184:5696-704. doi:10.4049/jimmunol.0903722
26. Muyldermans S. Single domain camel antibodies: current status. J Biotechnol (2001) 74:277-302
27. Nguyen VK, Su C, Muyldermans S, van der Loo W. Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics (2002) 54:39-47. doi:10.1007/s00251-002-0433-0
28. Daley LP, Gagliardo LF, Duffy MS, Smith MC, Appleton JA. Application of monoclonal antibodies in functional and comparative investigations of heavy-chain immunoglobulins in new world camelids. Clin Diagn Lab Immunol (2005) 12:380-6
29. Flajnik MF, Deschacht N, Muyldermans S. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol (2011) 9:e1001120. doi:10.1371/journal.pbio.1001120
30. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature (1989) 341:544-6. doi:10.1038/341544a0
31. Spinelli S, Desmyter A, Frenken L, Verrips T, Tegoni M, Cambillau C. Domain swapping of a llama VHH domain builds a crystal-wide beta-sheet structure. FEBS Lett (2004) 564:35-40. doi:10.1016/S0014-5793(04)00304-7
32. Decanniere K, Desmyter A, Lauwereys M, Ghahroudi MA, Muyldermans S, Wyns L. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure (1999) 7:361-70. doi:10.1016/S0969-2126(99)80049-5
33. Desmyter A, Spinelli S, Payan F, Lauwereys M, Wyns L, Muyldermans S, et al. Three camelid VHH domains in complex with porcine pancreatic a-amylase: inhibition and versatility of binding topology. J Biol Chem (2002) 277:23645-50. doi:10.1074/jbc.M202327200
34. Desmyter A, Decanniere K, Muyldermans S, Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem (2001) 276:26285-90. doi:10.1074/jbc.M102107200
35. Perez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, Darbon H, et al. Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry (2001) 40:74-83. doi:10.1021/bi0009082
36. Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, et al. Single-domain antibody fragments with high conformational stability. Protein Sci (2002) 11:500-15. doi:10.1110/ps.34602
37. Verheesen P, ten Haaft MR, Lindner N, Verrips CT, de Haard JJ. Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. Biochim Biophys Acta (2003) 1624:21-8. doi:10.1016/j.bbagen.2003.09.006
38. Eyer L, Hruska K. Single-domain antibody fragments derived from heavy-chain antibodies: a review. Vet Med (2012) 9:439-513
39. Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today (2016) 21:1076-113. doi:10.1016/j.drudis.2016.04.003
40. D'Huyvetter M, Aerts A, Xavier C, Vaneycken I, Devoogdt N, Gijs M, et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging (2012) 7:254-64. doi:10.1002/cmmi.491
41. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol (2009) 198:157-74. doi:10.1007/s00430-009-0116-7
42. Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol (2008) 8:600-8. doi:10.1016/j.coph.2008.07.006
43. Chakravarty R, Goel S, Cai W. Nanobody: the 'magic bullet' for molecular imaging? Theranostics (2014) 4:386-98. doi:10.7150/thno.8006
44. Fernandes CFC, Pereira SDS, Luiz MB, Zuliani JP, Furtado GP, Stabeli RG. Camelid single-domain antibodies as an alternative to overcome challenges related to the prevention, detection, and control of neglected tropical diseases. Front Immunol (2017) 8:653. doi:10.3389/fimmu.2017.00653
45. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol (2003) 21:484-90. doi:10.1016/j.tibtech.2003.08.007
46. Harmsen MM, van Solt CB, Fijten HP, van Keulen L, Rosalia RA, Weerdmeester K, et al. Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol (2007) 120:193-206. doi:10.1016/j.vetmic.2006.10.029
47. Vaneycken I, D'Huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol (2011) 22:877-81. doi:10.1016/j.copbio.2011.06.009
48. Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanobodies and their potential applications. Nanomedicine (Lond) (2013) 8:1013-26. doi:10.2217/nnm.13.86
49. Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem (2009) 284:3273-84. doi:10.1074/jbc.M806889200
50. Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(R) targeting the DR5 receptor. Cancer Chemother Pharmacol (2015) 75:887-95. doi:10.1007/s00280-015-2712-0
51. McGonigal K, Tanha J, Palazov E, Li S, Gueorguieva-Owens D, Pandey S. Isolation and functional characterization of single domain antibody modulators of caspase-3 and apoptosis. Appl Biochem Biotechnol (2009) 157:226-36. doi:10.1007/s12010-008-8266-4
52. Staus DP, Wingler LM, Strachan RT, Rasmussen SG, Pardon E, Ahn S, et al. Regulation of β2-adrenergic receptor function by conformationally selective single-domain intrabodies. Mol Pharmacol (2014) 85:472-81. doi:10.1124/mol.113.089516
53. Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies: African trypanosomes as paradigm. J Biol Chem (2004) 279:1256-61. doi:10.1074/jbc.M307341200
54. Bradley ME, Dombrecht B, Manini J, Willis J, Vlerick D, De Taeye S, et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Mol Pharmacol (2015) 87:251-62. doi:10.1124/mol.114.094821
55. Manglik A, Kobilka BK, Steyaert J. Nanobodies to study G protein-coupled receptor structure and function. Annu Rev Pharmacol Toxicol (2017) 57:19-37. doi:10.1146/annurev-pharmtox-010716-104710
56. Baker M. Upping the ante on antibodies. Nat Biotechnol (2005) 23:1065-72. doi:10.1038/nbt0905-1065
57. Beghein E, Gettemans J. Nanobody technology: a versatile toolkit for microscopic imaging, protein-protein interaction analysis, and protein function exploration. Front Immunol (2017) 8:771. doi:10.3389/fimmu.2017.00771
58. Rossey I, Gilman MS, Kabeche SC, Sedeyn K, Wrapp D, Kanekiyo M, et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat Commun (2017) 8:14158. doi:10.1038/ncomms14158
59. Darling TL, Sherwood LJ, Hayhurst A. Intracellular crosslinking of filoviral nucleoproteins with Xintrabodies restricts viral packaging. Front Immunol (2017) 8:1197. doi:10.3389/fimmu.2017.01197
60. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 23:1126-36. doi:10.1038/nbt1142
61. Vanlandschoot P, Stortelers C, Beirnaert E, Ibanez LI, Schepens B, Depla E, et al. Nanobodies(R): new ammunition to battle viruses. Antiviral Res (2011) 92:389-407. doi:10.1016/j.antiviral.2011.09.002
62. Unciti-Broceta JD, Del Castillo T, Soriano M, Magez S, Garcia-Salcedo JA. Novel therapy based on camelid nanobodies. Ther Deliv (2013) 4:1321-36. doi:10.4155/tde.13.87
63. De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol (2014) 32:263-70. doi:10.1016/j.tibtech.2014.03.001
64. Helma J, Cardoso MC, Muyldermans S, Leonhardt H. Nanobodies and recombinant binders in cell biology. J Cell Biol (2015) 209:633-44. doi:10.1083/jcb.201409074
65. Bever CS, Dong JX, Vasylieva N, Barnych B, Cui Y, Xu ZL, et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Anal Bioanal Chem (2016) 408:5985-6002. doi:10.1007/s00216-016-9585-x
66. Li J, Zhu Z. Research and development of next generation of antibody-based therapeutics. Acta Pharmacol Sin (2010) 31:1198-207. doi:10.1038/aps.2010.120
67. Mazor Y, Sachsenmeier KF, Yang C, Hansen A, Filderman J, Mulgrew K, et al. Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep (2017) 7:40098. doi:10.1038/srep40098
68. Holliger P, Winter G. Engineering bispecific antibodies. Curr Opin Biotechnol (1993) 4:446-9. doi:10.1016/0958-1669(93)90010-T
69. Rozan C, Cornillon A, Petiard C, Chartier M, Behar G, Boix C, et al. Single-domain antibody-based and linker-free bispecific antibodies targeting Fc-RIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther (2013) 12:1481-91. doi:10.1158/1535-7163.MCT-12-1012
70. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J (2002) 16:240-2
71. Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem (2005) 95:1201-14. doi:10.1111/j.1471-4159.2005.03463.x
72. Li T, Bourgeois JP, Celli S, Glacial F, Le Sourd AM, Mecheri S, et al. Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J (2012) 26:3969-79. doi:10.1096/fj.11-201384
73. Webster CI, Caram-Salas N, Haqqani AS, Thom G, Brown L, Rennie K, et al. Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1. FASEB J (2016) 30:1927-40. doi:10.1096/fj.201500078
74. Moutel S, Bery N, Bernard V, Keller L, Lemesre E, de Marco A, et al. NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife (2016) 5:e16228. doi:10.7554/eLife.16228
75. Monegal A, Ami D, Martinelli C, Huang H, Aliprandi M, Capasso P, et al. Immunological applications of single-domain llama recombinant antibodies isolated from a naive library. Protein Eng Des Sel (2009) 22:273-80. doi:10.1093/protein/gzp002
76. Goldman ER, Anderson GP, Liu JL, Delehanty JB, Sherwood LJ, Osborn LE, et al. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem (2006) 78:8245-55. doi:10.1021/ac0610053
77. Yan J, Li G, Hu Y, Ou W, Wan Y. Construction of a synthetic phage-displayed nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications. J Transl Med (2014) 12:343. doi:10.1186/s12967-014-0343-6
78. Ladenson RC, Crimmins DL, Landt Y, Ladenson JH. Isolation and characterization of a thermally stable recombinant anti-caffeine heavy-chain antibody fragment. Anal Chem (2006) 78:4501-8. doi:10.1021/ac058044j
79. Spinelli S, Frenken LG, Hermans P, Verrips T, Brown K, Tegoni M, et al. Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry (2000) 39:1217-22. doi:10.1021/bi991830w
80. Smolarek D, Hattab C, Hassanzadeh-Ghassabeh G, Cochet S, Gutierrez C, de Brevern AG, et al. A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines. Cell Mol Life Sci (2010) 67:3371-87. doi:10.1007/s00018-010-0387-6
81. Traenkle B, Emele F, Anton R, Poetz O, Haeussler RS, Maier J, et al. Monitoring interactions and dynamics of endogenous β-catenin with intracellular nanobodies in living cells. Mol Cell Proteomics (2015) 14:707-23. doi:10.1074/mcp.M114.044016
82. van der Linden RH, Frenken LG, de Geus B, Harmsen MM, Ruuls RC, Stok W, et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta (1999) 1431:37-46. doi:10.1016/S0167-4838(99)00030-8
83. Doyle PJ, Arbabi-Ghahroudi M, Gaudette N, Furzer G, Savard ME, Gleddie S, et al. Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol. Mol Immunol (2008) 45:3703-13. doi:10.1016/j.molimm.2008.06.005
84. Maussang D, Mujic-Delic A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, et al. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem (2013) 288:29562-72. doi:10.1074/jbc.M113.498436
85. McCoy LE, Rutten L, Frampton D, Anderson I, Granger L, Bashford-Rogers R, et al. Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog (2014) 10:e1004552. doi:10.1371/journal.ppat.1004552
86. Peyrassol X, Laeremans T, Gouwy M, Lahura V, Debulpaep M, Van Damme J, et al. Development by genetic immunization of monovalent antibodies (nanobodies) behaving as antagonists of the human ChemR23 receptor. J Immunol (2016) 196:2893-901. doi:10.4049/jimmunol.1500888
87. Liu S, Wang S, Lu S. DNA immunization as a technology platform for monoclonal antibody induction. Emerg Microbes Infect (2016) 5:e33. doi:10.1038/emi.2016.27
88. Nguyen VK, Zou X, Lauwereys M, Brys L, Bruggemann M, Muyldermans S. Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells. Immunology (2003) 109:93-101. doi:10.1046/j.1365-2567.2003.01633.x
89. Zou X, Smith JA, Nguyen VK, Ren L, Luyten K, Muyldermans S, et al. Expression of a dromedary heavy chain-only antibody and B cell development in the mouse. J Immunol (2005) 175:3769-79. doi:10.4049/jimmunol.175.6.3769
90. Janssens R, Dekker S, Hendriks RW, Panayotou G, van Remoortere A, San JK, et al. Generation of heavy-chain-only antibodies in mice. Proc Natl Acad Sci U S A (2006) 103:15130-5. doi:10.1073/pnas.0601108103
91. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-7. doi:10.1038/256495a0
92. Prentice HG, Blacklock HA, Janossy G, Bradstock KF, Skeggs D, Goldstein G, et al. Use of anti-T-cell monoclonal antibody OKT3 to prevent acute graft-versus-host disease in allogeneic bone-marrow transplantation for acute leukaemia. Lancet (1982) 1:700-3. doi:10.1016/S0140-6736(82)92619-8
93. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC, et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med (1981) 305:308-14. doi:10.1056/NEJM198108063050603
94. Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol (2010) 10:345-52. doi:10.1038/nri2747
95. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs (2015) 7:9-14. doi:10.4161/19420862.2015.989042
96. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. Annu Rev Immunol (1994) 12:433-55. doi:10.1146/annurev.iy.12.040194.002245
97. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol (2005) 23:1105-16. doi:10.1038/nbt1126
98. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol (2009) 27:331-7. doi:10.1038/nbt0409-331
99. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature (1990) 348:552-4. doi:10.1038/348552a0
100. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen. Biotechnology (N Y) (1994) 12:899-903
101. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNF-a monoclonal antibody D2E7. Ann Rheum Dis (1999) 58(Suppl 1):I70-2. doi:10.1136/ard.58.2008.i70
102. Wang Y, Fan Z, Shao L, Kong X, Hou X, Tian D, et al. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. Int J Nanomedicine (2016) 11:3287-303. doi:10.2147/IJN.S107194